Table 4 SMRs among patients with a first-time hospital-based diagnosis of HZ, Denmark, 1994–2012
Observed | Expected | SMR (95 % CI)a | |
|---|---|---|---|
Overall | 6059 | 3414 | 1.8 (1.7–1.8) |
Age group (years) | |||
0–9 | 12 | 1.1 | 10.7 (6.1–18.9) |
10–19 | 18 | 1.1 | 16.4 (10.4–26.1) |
20–29 | 34 | 4.0 | 8.5 (6.1–12.0) |
30–39 | 66 | 11 | 5.8 (4.6–7.4) |
40–49 | 143 | 30 | 4.8 (4.1–5.7) |
50–59 | 451 | 124 | 3.6 (3.3–4.0) |
60–69 | 916 | 350 | 2.6 (2.5–2.8) |
70–79 | 1874 | 988 | 1.9 (1.8–2.0) |
80–89 | 2080 | 1507 | 1.4 (1.3–1.4) |
≥ 90 | 465 | 397 | 1.2 (1.1–1.3) |
Sex | |||
Women | 3530 | 2166 | 1.6 (1.6–1.7) |
Men | 2529 | 1248 | 2.0 (1.9–2.1) |
Charlson Comorbidity Index level | |||
None | 1663 | 1651 | 1.0 (1.0–1.1) |
Moderate | 1229 | 784 | 1.6 (1.5–1.7) |
Severe | 1346 | 506 | 2.7 (2.5–2.8) |
Very severe | 1821 | 473 | 3.8 (3.7–4.0) |
Comorbidity associated with immune dysregulation | |||
No | 3378 | 2513 | 1.3 (1.3–1.4) |
Yes | 2681 | 901 | 3.0 (2.9–3.1) |
Any of the identified comorbidities | |||
No | 1532 | 1555 | 1.0 (0.9–1.0) |
Yes | 4527 | 1858 | 2.4 (2.4–2.5) |